Suppr超能文献

[赫利克索——用于癌症治疗的槲寄生制剂。文献编号19]

[Helixor--mistletoe preparation for cancer therapy. Documentation No. 19].

作者信息

Kast A, Hauser S P

出版信息

Schweiz Rundsch Med Prax. 1990 Mar 6;79(10):291-5.

PMID:2180032
Abstract

Helixor is an aqueous cold extract from fresh mistletoe, obtained from fir, pine and apple trees. A number of components with different possible effects were isolated: lectins, viscotoxins, alkaloids, etc. "Oncological therapy" and "stimulation of the bone marrow" are given as the main fields of indication. Pregnancy, hyperthyroidism and intolerances are given as contraindications. Depending on the type and the stage of the tumour, treatment based on a specific rhythmic schedule should be carried out for a period ranging from five years to a lifetime. A 7-ampoule pack costs 37 to 44 DM. Local inflammatory reactions occur as side effects. Fever is desirable. Helixor was developed by the Section for Leukemia and Cancer Therapy of the Gemein-schaft Fischermühle e. V. in Rosenfeld, FRG, and has been used since about 1968. It is produced and distributed by Helixor Heilmittel GmbH & Co. The origin of anticancer treatment with Helixor, a mistletoe preparation, is the anthroposophical medicine. In addition, Helixor supposedly bridges the dramatic gap between conventional and natural treatment of cancer in that it exerts both a selective cancerostatic and an immunostimulatory effect. Hardly any research has been done on the pharmacodynamics, the pharmacokinetics and the toxicity of the total extract Helixor. In vitro studies reveal a cytostatic effect on individual cell lines; animal experiments with freshly pressed juice are contradictory. Specific effects of Helixor on the immune system and its actual bearing on the tumour process have so far not been unequivocally elucidated. The three clinical-historical comparative studies contain methodological errors. They do not provide evidence of the clinical efficacy against tumours.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

赫利可素是一种从冷杉、松树和苹果树上获取的新鲜槲寄生的水性冷提取物。已分离出多种可能具有不同作用的成分:凝集素、槲寄生毒素、生物碱等。其主要适应症领域为“肿瘤治疗”和“骨髓刺激”。禁忌症包括妊娠、甲状腺功能亢进和不耐受情况。根据肿瘤的类型和阶段,应按照特定的节律方案进行为期五年至终身的治疗。一个7支安瓿的包装售价为37至44德国马克。副作用包括局部炎症反应。发热是预期效果。赫利可素由德意志联邦共和国罗森费尔德的Gemeinschaft Fischermühle e. V.的白血病和癌症治疗部门研发,自1968年左右开始使用。它由赫利可素医药有限公司生产和销售。用槲寄生制剂赫利可素进行抗癌治疗的起源是人类智慧医学。此外,赫利可素据称弥合了传统癌症治疗与自然癌症治疗之间的巨大差距,因为它兼具选择性抑制癌细胞生长和免疫刺激作用。几乎没有对赫利可素总提取物的药效学、药代动力学和毒性进行研究。体外研究显示对个别细胞系有细胞抑制作用;用新鲜压榨汁液进行的动物实验结果相互矛盾。赫利可素对免疫系统的具体作用及其对肿瘤进程的实际影响迄今尚未明确阐明。三项临床历史比较研究存在方法学错误。它们并未提供赫利可素对肿瘤临床疗效的证据。(摘要截选至250词)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验